Groupe Francophone des Myelodysplasies   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Paris France (2003)

Organization Overview

First Clinical Trial
2003
NCT00455910
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Groupe Francophone des Myélodysplasies | Groupe francophone des Myelodisplasies | Groupe Francophone des Myelodysplasies